ReviewClinical immunology (Orlando, Fla.)2020
SARS-CoV-2 infections in children and young people.
Review in Clinical immunology (Orlando, Fla.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 116 citations in OpenAlex.
- The Effect of Potassium Canrenoate (Mineralocorticoid Receptor Antagonist) on the Markers of Inflammation in the Treatment of COVID-19 Pneumonia and Fibrosis-A Secondary Analysis of Randomized Placebo-Controlled Clinical Trial.International journal of molecular sciences · 2023Trial
- A Longitudinal Exploratory Study of SARS-CoV-2 Antibody Dynamics in Young Adults in Bogotá: Lessons from Natural Infection and Post-Vaccination Memory.Biomedicines · 2026Article
- Risks and benefits of face masks in children.Frontiers in pediatrics · 2026Review
- Age-associated differences in mucosal and systemic host responses to SARS-CoV-2 infection.Nature communications · 2025Article
- COVID-19 vaccine acceptance and associated factors among parents of children between 6 and 12 years: a multicenter mixed method study in India.Frontiers in public health · 2025Article
- Bacterial and Viral Co-Infections in COVID-19 Patients: Etiology and Clinical Impact.Biomedicines · 2024Article
- A follow-up study on respiratory outcomes, quality of life and performance perception of SARS-CoV-2 primary and reinfection in elite athletes: A 9-month prospective study.European journal of sport science · 2024Article
- Centenarians, semi and supercentenarians, COVID-19 and Spanish flu: a serological assessment to gain insight into the resilience of older centenarians to COVID-19.Immunity & ageing : I & A · 2024Article
- Article
- Serological survey in a university community after the fourth wave of COVID-19 in Senegal.PloS one · 2024Article
- Epidemiology of COVID-19 among Children and Adolescents in Sudan 2020-2021.Epidemiologia (Basel, Switzerland) · 2023Article
- Article
- The Role of Immunity in the Pathogenesis of SARS-CoV-2 Infection and in the Protection Generated by COVID-19 Vaccines in Different Age Groups.Pathogens (Basel, Switzerland) · 2023Review
- Impact of vaccination and non-pharmacological interventions on COVID-19: a review of simulation modeling studies in Asia.Frontiers in public health · 2023Review
- Demographic, clinical and laboratory differences between paediatric acute COVID-19 and PIMS-TS-results from a single centre study in the UK.Frontiers in pediatrics · 2023Article
- Does Measles, Mumps, and Rubella (MMR) Vaccination Protect against COVID-19 Outcomes: A Nationwide Cohort Study.Vaccines · 2022Article
- COVID-19 in Portugal: a retrospective review of paediatric cases, hospital and PICU admissions in the first pandemic year.BMJ paediatrics open · 2022Article
- Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.Pharmacology & therapeutics · 2022Review
- Convalescent serum-derived exosomes: Attractive niche as COVID-19 diagnostic tool and vehicle for mRNA delivery.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- First Description of Serological Evidence for SARS-CoV-2 in Lactating Cows.Animals : an open access journal from MDPI · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Though recent reports link SARS-CoV-2 infections with hyper-inflammatory states in children, most children experience no/mild symptoms, and hospitalization and mortality rates are low in the age group. As symptoms are usually mild and seroconversion occurs at low frequencies, it remains unclear whether children significantly contribute to community transmission. Several hypotheses try to explain age-related differences in disease presentation and severity. Possible reasons for milder presentations in children as compared to adults include frequent contact to seasonal coronaviruses, presence of cross-reactive antibodies, and/or co-clearance with other viruses. Increased expression of ACE2 in young people may facilitate virus infection, while limiting inflammation and reducing the risk of severe disease. Further potential factors include recent vaccinations and a more diverse memory T cell repertoire. This manuscript reviews age-related host factors that may protect children from COVID-19 and complications associated, and addresses the confusion around seropositivity and immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.